Healthcare Industry News: HSMN NewsFeed
News Release - August 25, 2020
Smith & Nephew Launches ARIA Care Management Platform for Patients and ProvidersComprehensive digital solution is designed to support reduction of post-acute costs, improvement of clinical efficiencies and generation of value-based data sets
LONDON, Aug. 25, 2020 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (LSE:SN,NYSE:SNN), the global medical technology business, today announces the launch of ARIA, a digital platform and application designed to connect delivery of patient care with providers throughout the surgical and clinical episode. ARIA is powered by the company's Real Intelligence digital ecosystem and Positive Connections ASC solutions program.
The platform aims to help clinicians shorten the patient's post-acute recovery time, develop efficiencies that reduce costs, and generate key Patient Reported Outcome Measures (PROMs) and satisfaction data to better define value for both the patient and site of care. The platform contains customizable patient engagement pathways and enables connected, automated communication between the care navigator and patient. ARIA also displays dashboards that provide visibility for the patient and provider to help reduce variability in clinical outcomes.
In addition to those benefits, the platform also enables secure communication with referring providers and generates data that ambulatory surgery centers or clinical practices may utilize when interfacing with payers.
"Interconnectivity and communication have become core drivers of efficiency in every aspect of our lives," said Skip Kiil, President, Global Orthopaedics at Smith & Nephew. "ARIA will help our customers utilize digital connectivity with patients and their referral network to break down traditional barriers, improve patient compliance, and mitigate readmission risk using objective data."
Smith & Nephew acquired two digital technology products, MiJourney and Rapid Recovery Pathways, in February. The foundation for ARIA was built on MiJourney, and Rapid Recovery Pathways will be integrated into the platform later this year.
According to a white paper evaluating MiJourney's use in two hospitals and authored by its founders, the product generated documented cost savings and increased efficiency for customers and their patients, including:
- a 45 percent reduction in readmission rates for some customers, thanks to fully integrated patient communication and progress evaluation1
- an approximate 35 percent reduction in 90-day episodic costs1
- a reduced length of stay in skilled nursing facilities by up to 30 percent for patients when using the product1
To learn more about ARIA, or to register for a product demonstration, visit Think-ARIA.com.
1 Thomas, S. The Effect of a Navigational Tool on Total Joint Replacement in a Closed Health System. White paper, 2018
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith & Nephew is a constituent of the FTSE100 (LSE:SN,NYSE:SNN). The terms 'Group' and 'Smith & Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith & Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsNew data confirms Smith & Nephew technology as the best performing cementless construct for Total Hip Arthroplasty¹
Smith & Nephew announces RI.INSIGHTS - a global data analytics platform designed to advance the standard of care for robotics-assisted joint replacement procedures
Smith & Nephew launches NOVOSTITCH(TM) PRO Meniscal Repair System in Europe